CoChat

JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers

Open access
van der Velden, Jos L. J., Ye, Ying, Nolin, James D., Hoffman, Sidra M., Chapman, David G., Lahue, Karolyn G., Abdalla, Sarah, Chen, Peng, Liu, Yong, Bennett, Brydon, Khalil, Nasreen, Sutherland, Donna, Smith, William, Horan, Gerald, Assaf, Mahmoud, Horowitz, Zebulun, Chopra, Rajesh, Stevens, Randall M., Palmisano, Maria, Janssen‐Heininger, Yvonne M. W., Schafer, Peter H. · 2016 · Clinical and Translational Medicine
Cited by 125

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: Lung remodeling and pulmonary fibrosis are serious, life‐threatening conditions resulting from diseases such as chronic severe asthma and idiopathic pulmonary fibrosis (IPF). Preclinical evidence suggests that JNK enzyme function is required for key steps in the pulmonary fibrotic process. However, a selective JNK inhibitor has not been investigated in translational models of lung fibrosis with clinically relevant biomarkers, or in IPF patients. Methods: The JNK inhibitor CC‐930 was evaluated in the house dust mite‐induced fibrotic airway mouse model, in a phase I healthy volunteer pharmacodynamic study, and subsequently in a phase II multicenter study of mild/moderate IPF (n = 28), with a 4‐week, placebo‐controlled, double‐blind, sequential ascending‐dose period (50 mg QD, 100 mg QD, 100 mg BID) and a 52‐week open‐label treatment‐extension period. Results: In the preclinical model, CC‐930 attenuated collagen 1A1 gene expression, peribronchiolar collagen deposition, airway mucin MUC5B expression in club cells, and MMP‐7 expression in lung, bronchoalveolar lavage fluid, and serum. In the phase I study, CC‐930 reduced c‐Jun phosphorylation induced by UV radiation in skin. In the phase II IPF study, there was a CC‐930 dose‐dependent trend in reduction of MMP‐7 and SP‐D plasma protein levels. The most commonly reported adverse events were increased ALT, increased AST, and upper respiratory tract infection (six subjects each, 21.4 %). A total of 13 subjects (46.4 %) experienced adverse events that led to discontinuation of study drug. Nine out of 28 subjects experienced progressive disease in this study. The mean FVC (% predicted) declined after 26–32 weeks at doses of 100 mg QD and 100 mg BID. Changes in MMP‐7, SP‐D, and tenascin‐C significantly correlated with change in FVC (% predicted). Conclusions: These results illustrate JNK enzymatic activity involvement during pulmonary fibrosis, and support systemic biomarker use for tracking disease progression and the potential clinical benefit of this novel intervention in IPF. Trial registration ClinicalTrials.gov NCT01203943

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40169-016-0117-2

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 125

Metadata

Authors
van der Velden, J. L. J., Ye, Y., Nolin, J. D., Hoffman, S. M., Chapman, D. G., Lahue, K. G., Abdalla, S., Chen, P., Liu, Y., Bennett, B., Khalil, N., Sutherland, D., Smith, W., Horan, G., Assaf, M., Horowitz, Z., Chopra, R., Stevens, R. M., Palmisano, M., Janssen‐Heininger, Y. M. W., & Schafer, P. H.
Venue
Clinical and Translational Medicine
Publisher
Wiley
Published
2016-09-02
Volume
5
Issue
1
Pages
36-36
ISSN
2001-1326 (ISSN-L)
OpenAlex
W2507486366
Cited by
125
References
7
FWCI
6.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. https://app.cochat.ai/papers/10.1186/s40169-016-0117-2
The paper
van der Velden, J. L. J., Ye, Y., Nolin, J. D., Hoffman, S. M., Chapman, D. G., Lahue, K. G., Abdalla, S., Chen, P., Liu, Y., Bennett, B., Khalil, N., Sutherland, D., Smith, W., Horan, G., Assaf, M., Horowitz, Z., Chopra, R., Stevens, R. M., Palmisano, M., . . . Schafer, P. H. (2016). JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clinical and Translational Medicine. https://doi.org/10.1186/s40169-016-0117-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.